These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 23335275

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs.
    Armstrong EP, Skrepnek GH, Sasane M, Snodgrass SM, Ballas SK.
    J Med Econ; 2013; 16(1):10-8. PubMed ID: 22947171
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE, Hagiwara M, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease.
    Candrilli SD, O'Brien SH, Ware RE, Nahata MC, Seiber EE, Balkrishnan R.
    Am J Hematol; 2011 Mar; 86(3):273-7. PubMed ID: 21328441
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Serum angiogenin level in sickle cell disease and beta thalassemia patients.
    Matter RM, Abdelmaksoud AA, Shams MA, Bebawy EK.
    Pediatr Hematol Oncol; 2014 Feb; 31(1):50-6. PubMed ID: 24483841
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.
    Vekeman F, Cheng WY, Sasane M, Huynh L, Duh MS, Paley C, Mesa RA.
    Leuk Lymphoma; 2015 Feb; 56(10):2803-11. PubMed ID: 25676036
    [Abstract] [Full Text] [Related]

  • 19. The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease.
    Kang HA, Barner JC.
    J Manag Care Spec Pharm; 2020 Nov; 26(11):1412-1422. PubMed ID: 33119448
    [Abstract] [Full Text] [Related]

  • 20. Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004-2019.
    Tang AY, Zhou M, Maillis AN, Lai KW, Lane PA, Snyder AB.
    Pediatr Blood Cancer; 2023 Mar; 70(3):e30152. PubMed ID: 36579749
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.